WO2000032765A3 - Ribozyme therapy for the treatment and/or prevention of restenosis - Google Patents

Ribozyme therapy for the treatment and/or prevention of restenosis Download PDF

Info

Publication number
WO2000032765A3
WO2000032765A3 PCT/US1999/028772 US9928772W WO0032765A3 WO 2000032765 A3 WO2000032765 A3 WO 2000032765A3 US 9928772 W US9928772 W US 9928772W WO 0032765 A3 WO0032765 A3 WO 0032765A3
Authority
WO
WIPO (PCT)
Prior art keywords
restenosis
prevention
treatment
ribozymes
ribozyme therapy
Prior art date
Application number
PCT/US1999/028772
Other languages
French (fr)
Other versions
WO2000032765A9 (en
WO2000032765A2 (en
Inventor
Richard Tritz
Peter J Welch
Jack R Barber
Joan M Robbins
Original Assignee
Immusol Inc
Richard Tritz
Peter J Welch
Jack R Barber
Joan M Robbins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusol Inc, Richard Tritz, Peter J Welch, Jack R Barber, Joan M Robbins filed Critical Immusol Inc
Priority to EP99968074A priority Critical patent/EP1147189A2/en
Priority to AU24762/00A priority patent/AU2476200A/en
Publication of WO2000032765A2 publication Critical patent/WO2000032765A2/en
Publication of WO2000032765A3 publication Critical patent/WO2000032765A3/en
Publication of WO2000032765A9 publication Critical patent/WO2000032765A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3531—Hydrogen

Abstract

As an effective therapy for restenosis, this invention provides ribozymes and ribozyme delivery systems useful to treat or prevent restenosis. Methods of producing ribozymes and gene therapy utilizing these ribozymes also are provided.
PCT/US1999/028772 1998-12-04 1999-12-06 Ribozyme therapy for the treatment and/or prevention of restenosis WO2000032765A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP99968074A EP1147189A2 (en) 1998-12-04 1999-12-06 Ribozyme therapy for the treatment and/or prevention of restenosis
AU24762/00A AU2476200A (en) 1998-12-04 1999-12-06 Ribozyme therapy for the treatment and/or prevention of restenosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11095498P 1998-12-04 1998-12-04
US60/110,954 1998-12-04

Publications (3)

Publication Number Publication Date
WO2000032765A2 WO2000032765A2 (en) 2000-06-08
WO2000032765A3 true WO2000032765A3 (en) 2000-11-16
WO2000032765A9 WO2000032765A9 (en) 2002-08-29

Family

ID=22335836

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/028772 WO2000032765A2 (en) 1998-12-04 1999-12-06 Ribozyme therapy for the treatment and/or prevention of restenosis

Country Status (3)

Country Link
EP (1) EP1147189A2 (en)
AU (1) AU2476200A (en)
WO (1) WO2000032765A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770633B1 (en) 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
JP2003530309A (en) * 1999-10-26 2003-10-14 イミューソル インコーポレイテッド Ribozyme therapy for treating proliferative skin disease or proliferative eye disease
US6492173B1 (en) * 2001-08-01 2002-12-10 Isis Pharmaceuticals, Inc. Antisense inhibition of cyclin D2 expression
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
JP2006516548A (en) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト Drug delivery from rapidly gelled polymer compositions
WO2005014854A1 (en) 2003-08-08 2005-02-17 Licentia, Ltd. Materials and methods for colorectal cancer screening, diagnosis, and therapy
PL1866414T3 (en) * 2005-03-31 2012-10-31 Calando Pharmaceuticals Inc Inhibitors of ribonucleotide reductase subunit 2 and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026888A1 (en) * 1993-05-19 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1997010334A2 (en) * 1995-09-12 1997-03-20 Immusol, Inc. Ribozyme therapy for the treatment and/or prevention of restenosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026888A1 (en) * 1993-05-19 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1997010334A2 (en) * 1995-09-12 1997-03-20 Immusol, Inc. Ribozyme therapy for the treatment and/or prevention of restenosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEV V ET AL: "RIBOZYMES TO CELL DIVISION CYCLE (CDC-2) KINASE AND PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) PREVENT INTIMAL HYPERPLASIA IN RAT CAROTID ARTERY", CIRCULATION,US,AMERICAN HEART ASSOCIATION, DALLAS, TX, vol. 92, no. 8, 15 October 1995 (1995-10-15), pages S34, XP000616561, ISSN: 0009-7322 *
GRASSI G ET AL: "Growth inhibition of smooth muscle cells from human coronary plaque tissues by hammerhead ribozymes", PATHOLOGY RESEARCH AND PRACTICE, vol. 194, 1998, pages 267, XP000910797 *

Also Published As

Publication number Publication date
EP1147189A2 (en) 2001-10-24
WO2000032765A9 (en) 2002-08-29
WO2000032765A2 (en) 2000-06-08
AU2476200A (en) 2000-06-19

Similar Documents

Publication Publication Date Title
WO2001023405A3 (en) Therapeutic treatment of androgen receptor driven conditions
WO2002059373A3 (en) Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
WO2000032765A3 (en) Ribozyme therapy for the treatment and/or prevention of restenosis
ZA200200085B (en) Methods of treating and/or suppressing weight gain.
WO2001000244A3 (en) METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
WO2004009610A3 (en) Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
WO1998036730A3 (en) Compositions for treating acne rosacea
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2000021513A3 (en) Methods for treating multiple sclerosis
ZA200003236B (en) Combination therapy for the treatment of migraine.
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
WO2001091789A3 (en) Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer
WO1997010334A3 (en) Ribozyme therapy for the treatment and/or prevention of restenosis
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
AU6726700A (en) Method of treating 1,1,1,3,3-pentafluoropropane
ZA200003235B (en) Combination therapy for the treatment of migraine.
ZA200002338B (en) Combination therapy for the treatment of migraine.
SI1140119T1 (en) Use OF LOW MOLECULAR WEIGHT HEPARIN for the prevention and/or treatment of motoneuronal diseases
ZA200101188B (en) DNAzymes and methods for treating restenosis.
EP0750503A4 (en) Ribozyme therapy for restenosis
IL139303A0 (en) Treatment of arthritis and other similar conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999968074

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999968074

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 1999968074

Country of ref document: EP